ELND-002

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameELND-002
Drug Alias NameELND-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-4 antagonists
TargetsIntegrin alpha-4
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPerrigo Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElan Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A